Calithera is a biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.  Calithera is evaluating telaglenastat, a glutaminase inhibitor, in combination with standard of care therapies in a global, randomized trial in patients with advanced renal cell carcinoma, as well as a randomized trial in patients with non-small cell lung cancer with KEAP1/NRF2 mutations. Calithera is also developing an arginase inhibitor and a pipeline of additional novel tumor metabolism candidates.

About Telaglenastat

Telaglenastat (CB-839) is an investigational, first-in-class, novel glutaminase inhibitor specifically designed to block cancer cells from using glutamine for growth and survival. Tumors commonly exhibit metabolic alterations that increase their dependence on glutamine. In preclinical studies, telaglenastat produced synergistic antitumor effects when used in combination with standard-of-care therapies. Calithera is evaluating telaglenastat in combination therapy approaches for multiple solid tumor types, including metastatic renal cell carcinoma and non-small cell lung cancer.  The CANTATA trial (NCT03428217) is evaluating the efficacy and safety of telaglenastat in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic RCC.  Calithera expects to report top-line data from the CANTATA trial in late fourth quarter of 2020 or early first quarter 2021.

For more information about Calithera and Telaglenastat, please visit https://www.calithera.com/

Contact Information
Susan Demo, PhD
VP of Medical Affairs
[email protected]

Click the following images for printable/downloadable PDFs:

KidneyCAN thanks Calithera for their generous contribution in support of #KCRS20 as a Community Partner.